文献速递糖尿病肥胖与代谢综合征

GLP-1受体激动剂起始治疗时联用二甲双胍的胃肠道不良事件发生情况:LEADER、STEP 2、SUSTAIN-6和PIONEER 6的事后分析

Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.
PubMed 文献 · Diabetes Care · 2024-01-01

该事后分析利用LEADER、STEP 2、SUSTAIN-6和PIONEER 6四项临床试验数据,比较联用与未联用二甲双胍者在GLP-1受体激动剂起始和滴定期间胃肠道不良事件的发生率。在16,996例参与者中,12,928例(76%)接受二甲双胍治疗;联用二甲双胍未增加胃肠道不良事件的发生率或严重程度,也未增加研究药物停用。

要点

  • 在GLP-1受体激动剂起始和滴定期间,联用二甲双胍未增加胃肠道不良事件的发生率或严重程度。
  • 发生胃肠道不良事件者中,联用二甲双胍未增加研究药物停用。
  • 在各治疗组内,未联用二甲双胍者发生胃肠道不良事件和停用研究药物的比例在数值上高于联用者。

核心结论

  • 联用二甲双胍不增加GLP-1受体激动剂起始治疗期间胃肠道症状的发生,也不影响GLP-1受体激动剂停用。

研究设计与样本

  • 事后分析,利用LEADER、STEP 2、SUSTAIN-6和PIONEER 6四项关于利拉鲁肽和司美格鲁肽的临床试验数据。
  • 共纳入16,996例参与者,其中12,928例(76%)接受二甲双胍治疗。
  • 比较联用与未联用二甲双胍者在GLP-1受体激动剂起始和滴定期间胃肠道不良事件的发生率。

主要发现

  • 联用二甲双胍未增加观察窗口内发生胃肠道不良事件的参与者百分比或其严重程度。
  • 在发生胃肠道不良事件的参与者中,联用二甲双胍未增加研究药物停用。
  • 在各治疗组内(GLP-1受体激动剂组和安慰剂组),未联用二甲双胍者发生胃肠道不良事件和停用研究药物的百分比在数值上高于联用二甲双胍者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of concomitant metformin use on gastrointestinal adverse events during the initiation and titration of a glucagon-like peptide 1 receptor agonist (GLP-1RA). RESEARCH DESIGN AND METHODS: Using data from four clinical trials of liraglutide and semaglutide (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER], Semaglutide Treatment Effect in People with Obesity [STEP 2], Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6], and Peptide Innovation for Early Diabetes Treatment [PIONEER] 6), we compared the incidence of gastrointestinal adverse events during GLP-1RA initiation and titration in participants with and without concomitant metformin use. RESULTS: Of 16,996 participants, 12,928 (76%) were treated with metformin. Concomitant metformin use did not increase the percentage of participants who developed gastrointestinal adverse events or their severity during the observation window. Among participants experiencing gastrointestinal adverse events, metformin use did not increase study product discontinuation. Within treatment arms (GLP-1RA and placebo), a numerically higher percentage of metformin nonusers experienced gastrointestinal adverse events and discontinued the study product compared with metformin users. CONCLUSIONS: Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Klein KR, Clemmensen KKB, Fong E, et al. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. 2024. PMID: 38048543. doi:10.2337/dc23-1791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。